ERBB2 and malignant colon neoplasm: have revealed that pristimerin inhibits the phosphorylation of EGFR and HER2 in colon cancer cells, followed by the suppression of downstream ERK1/2, Akt, mTOR and NF-κB signaling pathways (38).